Published in Hepatology on August 01, 1997
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry (2005) 1.58
Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol (2001) 1.50
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol (2006) 1.28
Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc Natl Acad Sci U S A (2001) 1.07
Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob Agents Chemother (2003) 1.05
Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci (2004) 1.04
Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS Negl Trop Dis (2011) 1.03
Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One (2011) 0.99
Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut (2005) 0.98
Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol (2011) 0.94
Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS Negl Trop Dis (2013) 0.91
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver Int (2012) 0.90
A novel nucleoside analog, 1-beta-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro. Antiviral Res (2010) 0.89
Pure red cell aplasia caused by pegylated interferon-α-2a plus ribavirin in the treatment of chronic hepatitis C. World J Gastroenterol (2011) 0.88
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
Evolution of plant-made pharmaceuticals. Int J Mol Sci (2011) 0.85
Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis (2008) 0.83
Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. World J Gastroenterol (2013) 0.82
Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res (2015) 0.82
Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats. Antimicrob Agents Chemother (2002) 0.81
Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway. PLoS One (2012) 0.81
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. Clin Mol Hepatol (2012) 0.80
Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat (2010) 0.79
Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials. Hepat Mon (2016) 0.77
Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C. Pharmacopsychiatry (2014) 0.77
Efficacy and tolerability of combination therapy with interferon-alfa plus ribavirin in patients with chronic hepatitis C virus infection: a single-center study in relapsers and nonresponders to previous treatment with high-dose interferon-alfa monotherapy. Curr Ther Res Clin Exp (2003) 0.77
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. J Gastroenterol (2006) 0.77
Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin. Med Sci Monit (2011) 0.77
Long-term treatment with the combination of amantadine and ribavirin in hepatitis C nonresponders. A case series. Dig Dis Sci (2007) 0.76
Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. Dig Dis Sci (2003) 0.76
Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World J Gastroenterol (2015) 0.76
Approach to Anemia in Hospitalized Patients with Infectious Diseases; Is it Appropriate? Iran J Pharm Res (2015) 0.75
Recent advances in antiviral therapy. J Clin Pathol (1999) 0.75
Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Aliment Pharmacol Ther (2012) 0.75
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients. Clin Mol Hepatol (2012) 0.75
Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis. Curr Ther Res Clin Exp (2005) 0.75
Hepatitis C virus management: potential impact of nanotechnology. Virol J (2017) 0.75
Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. Dig Dis Sci (2001) 0.75
Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C. Dig Dis Sci (2001) 0.75
Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis (1989) 6.49
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis (2000) 6.05
Illnesses associated with Escherichia coli O157:H7 infections. A broad clinical spectrum. Ann Intern Med (1988) 5.92
Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med (2000) 5.27
CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXXIV. COMPARATIVE STUDIES ON THE NUTRITIVE VALUE OF ORALLY AND INTRAVENOUSLY ADMINISTERED HUMAN SERUM ALBUMIN IN MAN. J Clin Invest (1948) 5.08
A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA (1994) 4.85
Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med (1991) 4.68
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet (1993) 4.51
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions. J Virol (1987) 3.28
Hiccups: causes and cures. J Clin Gastroenterol (1985) 3.25
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab (1999) 3.00
The canals of Hering and hepatic stem cells in humans. Hepatology (1999) 2.93
Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology (2000) 2.83
Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA (1989) 2.73
Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology (1984) 2.72
Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med (1976) 2.67
An outbreak of Escherichia coli O157:H7 infection from unpasteurized commercial apple juice. Ann Intern Med (1999) 2.56
Hepatic angiomyolipoma: a clinicopathologic study of 30 cases and delineation of unusual morphologic variants. Am J Surg Pathol (1999) 2.53
Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem (2000) 2.47
Pattern formation by lateral inhibition with feedback: a mathematical model of delta-notch intercellular signalling. J Theor Biol (1996) 2.45
Spatial localization of the K+ channel selectivity filter by mutant cycle-based structure analysis. Neuron (1996) 2.38
Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med (1983) 2.36
Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem (2000) 2.30
Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med (1978) 2.30
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med (1978) 2.29
Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet (1993) 2.23
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology (1993) 2.20
The antigenic relationship of alcohol-soluble substances of corpus luteum to those of testis and brain. Am J Pathol (1941) 2.15
A statewide outbreak of Escherichia coli O157:H7 infections in Washington State. Am J Epidemiol (1990) 2.13
Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection. J Hepatol (1993) 2.12
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med (1997) 2.09
Comfrey herb tea-induced hepatic veno-occlusive disease. Am J Med (1989) 2.09
Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis (1995) 2.07
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1991) 2.06
HMB-45 reactivity in adrenal pheochromocytomas. Arch Pathol Lab Med (1992) 2.03
Liver transplantation in hemophilia A. Blood (1987) 1.98
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology (2000) 1.97
Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med (1981) 1.96
A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. J Immunol (1986) 1.93
Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis (2000) 1.87
The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology (1992) 1.85
Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology (1999) 1.84
Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology (1998) 1.84
Intestinal obstruction due to bezoars. Am J Gastroenterol (1984) 1.83
Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol (1997) 1.82
Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet (1978) 1.82
Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology (1990) 1.77
Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology (1983) 1.76
Positional information in chick limb morphogenesis. Nature (1973) 1.76
Hepatic 'stem cell' malignancies in adults: four cases. Histopathology (2003) 1.73
Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops. Am J Epidemiol (2001) 1.71
The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol (1997) 1.63
Blood use in liver transplantation. Transfusion (1987) 1.63
A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med (1987) 1.61
Efficacy of hepatitis B immune serum globulin after accidental exposure. Preliminary report of the Veterans Administration Cooperative Study. Lancet (1975) 1.59
Telomerase activity in precancerous hepatic nodules. Cancer (1998) 1.59
Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant (2011) 1.56
Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med (1996) 1.56
Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis. Lancet (1994) 1.55
Organ transplantation in HIV-positive patients with hemophilia. N Engl J Med (1990) 1.52
Asymptomatic structural liver disease in hemophilia. N Engl J Med (1978) 1.50
Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women? Hepatology (1984) 1.49
Oestrogen receptor B-region polymorphism and spontaneous abortion in women with breast cancer. Lancet (1990) 1.49
A new system for defining endoscopic complications emphasizing the measure of importance. Gastrointest Endosc (1997) 1.48
Hepatitis C virus infection in kidney transplant recipients. Hepatology (1993) 1.46
Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology (1989) 1.45
Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci (1997) 1.44
Molecular and cellular pathology of hepatitis B. Lab Invest (1985) 1.43
Detection of hepatitis B and hepatitis C viral sequences in fulminant hepatic failure of unknown etiology. Am J Clin Pathol (1995) 1.43
Diagnostic yield of a positive fecal occult blood test found on digital rectal examination. Does the finger count? Arch Intern Med (1991) 1.42
Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology (1996) 1.42
HLA-DR expression in bile duct damage in hepatitis C. Mod Pathol (1993) 1.42
The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis. Arch Pathol Lab Med (1998) 1.42
Hepatitis C testing. Comparison of Ortho's EIA and RIBA II tests in 1,182 patients undergoing primary liver transplantation. Am J Clin Pathol (1992) 1.42
THE COAGULATION DEFECT IN HEMOPHILIA: THE EFFECT, IN HEMOPHILIA, OF THE PARENTERAL ADMINISTRATION OF A FRACTION OF THE PLASMA GLOBULINS RICH IN FIBRINOGEN. J Clin Invest (1945) 1.41
Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol (1997) 1.39
Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology (1987) 1.39
DEANTIGENATED BEEF BLOOD PLASMA AS A POSSIBLE SUBSTITUTE FOR HUMAN BLOOD PLASMA. Science (1943) 1.39
Suction curettage for 'menstrual regulation' (MR). Adv Plan Parent (1974) 1.38
Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology (1984) 1.38
Investigation of multidrug-resistant Salmonella serotype typhimurium DT104 infections linked to raw-milk cheese in Washington State. JAMA (1999) 1.38
Distribution of five antigens in hepatocellular carcinoma. Lab Invest (1979) 1.35
Detection of circulating DNA by counterimmunoelectrophoresis (CIE). Arthritis Rheum (1973) 1.33
Meckel's diverticulum: pitfalls in scintigraphic detection in the adult. Am J Gastroenterol (1984) 1.33
Hepatic epithelioid hemangioendothelioma: resection or transplantation, which and when? Liver Transpl Surg (1999) 1.32
Liver transplantation in a hemophiliac. N Engl J Med (1985) 1.32
The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med (2001) 1.30
Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med (1984) 1.30
Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol (1998) 1.30
High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am J Transplant (2011) 1.29
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res (1983) 1.29
Complementary and alternative medicine in chronic liver disease. Hepatology (2001) 1.29
Genetic Considerations in Familial Hemorrhagic Disease. I. The Sex-Linked Recessive Disorders, Hemophilia and PTC Deficiency. Am J Hum Genet (1963) 1.27
Identification of bipotential progenitor cells in human liver regeneration. Lab Invest (1996) 1.26
Antithrombin Pittsburgh: an alpha1-antitrypsin variant causing hemorrhagic disease. Blood (1978) 1.26